delorazepam

PreclinicalSmall molecule

UUniversity of Turin, Italy

delorazepam is one of 45 small molecule programs targeting Eating Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eating DisorderActive, not recruiting

Eating DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

55 competitors in Eating Disorder

#DrugCompanyPhaseTrials

Atarax

Pfizer

Approved

1 2

Namenda

AbbVie

Approved

1 3

Cymbalta

Alnylam Pharmaceuticals

Approved

1 4

Victoza

Novo Nordisk

Approved

—5

Sunosi

AAxsome Therapeutics, Inc.

Approved

2 6

Strattera

MMap77

Approved

1 7

E-Mycin

AAzurity Pharmaceuticals

Approved

—8

Zonegran

AAzurity Pharmaceuticals

Zyprexa

Vyvanse

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eating Disorder1 trial

Neurobiology of Eating Disorders Treatments

Completed·UUniversity of Turin, Italy·N/A·NCT01990755·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for delorazepam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — delorazepam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for delorazepam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Turin, Italy company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Turin, Italy

delorazepam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eating Disorder1 trial

References

Drug Info

Quick Facts

Related News